^
Association details:
| Biomarker: | MLL2 mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug Class: | Immunotherapy |
| Direction: | Sensitive |
Evidence:
Source:
Title:
EP16.01-007 - Molecular Characterization by Next-Generation Sequencing (NGS) of Patients with Non-Small Cell Lung Cancer (NSCLC) Treated with Immunotherapy
Published date:
07/12/2022
Excerpt:
We conducted a retrospective study, which included patients diagnosed with NSCLC in our hospital from Jul-15 to Jan-21 and treated with immunotherapy...Note that in the group of MLL2 mutated, PFS was 8.6 months (CI: 1.5-15.8) vs 13.3 months in the MLL2 wild-type group (CI, not reached). This data could indicate a better response to immunotherapy in this subgroup.
